Login to Your Account

No pain for Colucid on phase III migraine data

By Randy Osborne
Staff Writer

Tuesday, September 6, 2016

A slightly higher-than-previous placebo response on the primary endpoint of two hours' freedom from headache did little to take the shine off top-line phase III migraine data disclosed by Colucid Pharmaceuticals Inc. with lasmiditan tablets in the trial known as SAMURAI.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription